Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Vitekta
Elvitegravir is an integrase strand transfer inhibitor (INSTI) used as part of combination antiretroviral therapy (cART) for the treatment of HIV-1 infection in adults. It blocks the action of integrase, a viral enzyme crucial for HIV replication by preventing the integration of viral DNA into the host cell's DNA. This inhibits the virus from multiplying and infecting new cells.
For the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.
Outcome:
Reduced elvitegravir levels
Mechanism:
Induction of CYP3A4 enzyme
Outcome:
Reduced elvitegravir absorption
Mechanism:
Chelation/altered gastric pH
Outcome:
May affect elvitegravir absorption
Mechanism:
Altered gastric motility
Most likely new formulation: Long-acting injectable elvitegravir (2025, 75% confidence)
Based on current usage trends and clinical trial data, there is a high likelihood (>90%) of elvitegravir remaining a key component of HIV treatment regimens in the next 5 years.
Antiretroviral, Integrase Inhibitor
Integrase Strand Transfer Inhibitor